1. 363OTreatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). (24th November 2019) Authors: Lee, D H; Subbiah, V; Gainor, J F; Taylor, M H; Zhu, V W; Doebele, R C; Lopes, G; Baik, C; Garralda, E; Gadgeel, S M; Kim, D-W; Turner, C D; Palmer, M; Miller, S; Curigliano, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. (24th May 2019) Authors: Mazieres, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, A B; Mezquita, L; Thai, A A; Mascaux, C; Couraud, S; Veillon, R; Van den Heuvel, M; Neal, J; Peled, N; Früh, M; Ng, T L; Gounant, V; Popat, S; Diebold, J; Sabari, J; Zhu, V W Journal: Annals of oncology Issue: Volume 30:Number 8(2019) Page Start: 1321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The allure of 'ALUR'. (24th April 2018) Authors: Nagasaka, M; Zhu, V W; Ou, S -H I Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1344 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗